Epic Bio to Present at the Upcoming CRISPR2.0 Conference
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced a presentation at the upcoming CRISPR2.0 conference being held November 28-30, 2023, at the Hilton Boston Back Bay, Boston Massachusetts.
Title: GEMS: CRISPR Epigenetics Platform to Revolutionize Genetic Medicine Track: Tech Innovation Session: Epigenetics: Harnessing Nature's Mechanism for Genome Regulation Session Date: Wednesday, November 29, 2023 Presentation Time: 1:30 p.m. ET
About Epic Bio Epic Bio is a leading epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company's proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. Epic's lead program, EPI-321, is in IND-enabling studies for the treatment of facioscapulohumeral muscular dystrophy (FSHD); additional programs seek to address alpha-1 antitrypsin deficiency (A1AD), heterozygous familial hypercholesterolemia (HeFH), and other indications. Visit www.epic-bio.com for more information or follow us on Twitter and LinkedIn.
Investor Contact
Shawn M. Cox Epic Bio Manager, Investor Relations, and Corporate Communications [email protected]
Media Contact
Lisa Raffensperger Ten Bridge Communications [email protected] (617) 903-8783
DiscoverU Health, a pioneering concierge medicine practice led by a commitment to minority health, is thrilled to announce the launch of its newest initiative, "Bridging Health Equity by 2025 - A Call to Minority Businesses". This campaign seeks to...
Two of New Jersey's most prestigious recognition platforms formally announced their strategic partnership today at the Russ Berrie Making a Difference Awards (MADA) ceremony held at Ramapo College. With a common goal of elevating public service in...
"As I entered my twenty-year long tenure as a labor and delivery registered nurse, I often pondered if there was a way of accounting and documenting my presence at a patient's bedside, primarily during an emergency," said an inventor, from Rio...
Biologics Safety Testing Market in terms of revenue was estimated to be worth $4.2 billion in 2024 and is poised to reach $7.2 billion by 2029, growing at a CAGR of 11.1% from 2024 to 2029 according to a new report by MarketsandMarketstm.
Some...
Charter Oak State College (http://www.CharterOak.edu/FinishCollege) offers a virtual Undergraduate Open House Wednesday, June 12, 2024, 5:30 PM ET via Zoom for prospective...
Eye disease and trauma are common among many animals including dogs, cats, horses, rabbits and snakes but all too often, veterinarians need to refer those patients to a specialist because they lack the skills or confidence to treat the animals...